AKCEA-TTR-LRx
- Generic Name
- AKCEA-TTR-LRx
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1637600-16-8
- Unique Ingredient Identifier
- 0GRZ0F5XJ6
- Background
AKCEA-TTR-LRx is under investigation in clinical trial NCT04136184 (Neuro-ttransform: A Study to Evaluate the Efficacy and Safety of Akcea-ttr-lrx in Participants With Hereditary Transthyretin-mediated Amyloid Polyneuropathy).
- Associated Conditions
- -
- Associated Therapies
- -
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06194825
- Locations
- 🇨🇳
Research Site, Xi'an, China
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT05667493
- Locations
- 🇮🇹
Azienda Ospedaliera - Universitaria Sant' Andrea, Roma, Italy
🇵🇹Unidade Local de Saúde de São José, E. P. E - Hospital de Santa Marta, Lisbon, Portugal
🇪🇸Complejo Hospitalario Universitario de Santiago (CHUS), Santiago De Compostela, Spain
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05071300
- Locations
- 🇫🇷
Hôpital de la Timone, Marseille, France
🇪🇸Hospital ClÃnico San Carlos, Madrid, Spain
🇪🇸Hospital Son Llà tzer, Palma De Mallorca, Spain
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04302064
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 1438
- Registration Number
- NCT04136171
- Locations
- 🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04136184
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸Indiana University School of Medicine - Indianapolis, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.